Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on...
JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on...
LONDON, Sept. 14, 2023 /PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "Healthcare Cognitive Computing...
The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for...
Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the...
Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE)...
CHATHAM, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
The Company’s development pipeline now includes three projects with UCLALEHI, Utah, Sept. 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a...
New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership...
Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic...
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers...
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)ALBANY, N.Y., Sept. 13,...
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE...
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests...
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS...
COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract...
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber...
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Significant progress made and well positioned for future growthLONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),...
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate...